Last reviewed · How we verify

Risk of asthma in offspring

AstraZeneca · Phase 2 active Small molecule

Risk of asthma in offspring is a Small molecule drug developed by AstraZeneca. It is currently in Phase 2 development.

At a glance

Generic nameRisk of asthma in offspring
SponsorAstraZeneca
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Risk of asthma in offspring

What is Risk of asthma in offspring?

Risk of asthma in offspring is a Small molecule drug developed by AstraZeneca.

Who makes Risk of asthma in offspring?

Risk of asthma in offspring is developed by AstraZeneca (see full AstraZeneca pipeline at /company/astrazeneca).

What development phase is Risk of asthma in offspring in?

Risk of asthma in offspring is in Phase 2.

Related